ClinConnect ClinConnect Logo
Search / Trial NCT03666052

Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration

Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Sep 10, 2018

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Children And Adolescent High Myopia Prospective Study

ClinConnect Summary

1. introduction 1.1 Overview of myopia and high myopia Myopia is the most common eye disease in the world . Among them, the incidence and prevalence of myopia are highest in developed countries and regions in East and Southeast Asia. It is predicted that by 2050, global myopia patients would reach 5 billion, 1 billion of which were high myopia. In developed countries and regions in East and Southeast Asia, the prevalence of myopia in high school graduates is as high as 80% to 90%. A study in Taiwan showed that more than 80% of adolescents suffered from myopia when they graduated from high s...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Children and adolescents between the ages of 4 and 18 years old, SE ≤ -4 D under 5 years old, SE ≤ -6 D at 6-8 years old, SE ≤ -8 D over 9 years old;
  • No eye disease, good general condition, can cooperate with the examiner;
  • Obtaining the consent of the child and his/her guardian;
  • Long-term residence in this city, there is no plan to move out of this city in the short term.
  • Exclusion Criteria:
  • Amblyopia (best corrected visual acuity (BCVA) less than 0.8 for children over 6 years old, BCVA less than 0.63 for children 6 years old and younger) and strabismus;
  • Secondary myopia, genetic disease or connective tissue-related myopia;
  • Moderate or severe ptosis;
  • Congenital cataract, glaucoma;
  • Other fundus diseases other than myopic related fundus lesions;
  • Intraocular or refractive surgery history;
  • The refractive medium is turbid, and it is impossible to take a clear fundus image;
  • Unable to cooperate with fundus image shooting and other examination;
  • Do not receive cycloplegia or have contraindications;
  • Poor overall condition, unable to follow up for a long time;
  • The child or the guardian refuses to participate in the research;
  • Other cases in which the researcher judges that it is not suitable for participation in the study.

About Shanghai Eye Disease Prevention And Treatment Center

The Shanghai Eye Disease Prevention and Treatment Center is a leading clinical research organization dedicated to advancing the understanding and treatment of ocular diseases. With a strong emphasis on innovation and patient-centered care, the center collaborates with various stakeholders, including academic institutions and healthcare providers, to conduct rigorous clinical trials. Its mission is to enhance eye health outcomes through evidence-based research, contributing to the global body of knowledge in ophthalmology. The center is committed to fostering a culture of excellence in clinical practices, ensuring the highest standards of safety and efficacy in all its research endeavors.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Xu Xian

Principal Investigator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials